[{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Pterostilbene","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pterostilbene","moa":"NLRP3","graph1":"Oncology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pterostilbene","moa":"NLRP3","graph1":"Neurology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pterostilbene","moa":"NLRP3","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Therapeutic Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pterostilbene","moa":"NLRP3","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Therapeutic Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pterostilbene","moa":"NLRP3","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Lo.Li. Pharma International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Green Tea Extract","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lo.Li. Pharma International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lo.Li. Pharma International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lo.Li. Pharma International \/ Not Applicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Broccoli Extract","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Pharmass\u00eatX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Green Tea Extract","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Pharmass\u00eatX","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Pharmass\u00eatX \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmass\u00eatX \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Green Tea Extract

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : PSX-514 (epigallocatechin gallate) is a small molecule, amyloid precursor protein (APP) inhibitor indicated for the treatment of inflammatory bowel disease pouchitis.

                          Brand Name : PSX-514

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 10, 2024

                          Lead Product(s) : Green Tea Extract

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Phase III Adult Stem Cell Company Covers Ability of its COVID-19 Nutraceutical to Repair Injured Brain Cells and Stimulate Endogenous Brain Stem Cells comprising administration of green tea and/or an extract.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 28, 2022

                          Lead Product(s) : Green Tea Extract,Nigella Sativa Extract,Broccoli Extract

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Pervistop (Epigallocatechin Gallate) once-daily supplement provides a true alternative to eradicating the root problem of HPV persistence, which can unpredictably evolve into cancer.

                          Brand Name : Pervistop

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 01, 2022

                          Lead Product(s) : Green Tea Extract,Hyaluronic Acid,Vitamin B12

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : JadiCells, as well as QuadraMune®, a commercially available nutraceutical developed by the Company have been shown to reduce lung scarring in other experiments.

                          Brand Name : QuadraMune

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 22, 2021

                          Lead Product(s) : Pterostilbene,Green Tea Extract,Sulforaphane

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Using a standard test for natural killer cell activity, the K562 lysis assay, 12 healthy volunteers taking one week of placebo had an average activity of 2.3 (±0.6), whereas those taking one week of QuadraMune™ had an average activity of 5.2 (±1.2), ...

                          Brand Name : QuadraMune

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 24, 2020

                          Lead Product(s) : Pterostilbene,Green Tea Extract,Sulforaphane

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : QuadraMune™ is a nutraceutical developed by the Company which is currently in a clinical trial for prevention of COVID-19[1]. Minocycline is an antibiotic that is approved by the FDA.

                          Brand Name : QuadraMune

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 28, 2020

                          Lead Product(s) : Pterostilbene,Green Tea Extract,Sulforaphane

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Undisclosed

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Pterostilbene is one of four ingredients which comprise QuadraMune™, a nutraceutical being developed by the Company which is currently in a clinical trial for prevention of COVID-19.

                          Brand Name : QuadraMune

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 28, 2020

                          Lead Product(s) : Pterostilbene,Green Tea Extract,Sulforaphane

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : In a series of animal studies using the triple-negative breast cancer 4T1 mouse model, the Company showed that administration of QuadraMune™ reduced lung metastasis on its own and increased efficacy of a “cancer vaccine.

                          Brand Name : QuadraMune

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 11, 2020

                          Lead Product(s) : Pterostilbene,Green Tea Extract,Sulforaphane

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Administration of daily doses of QuadraMune™ in healthy volunteers results in statistically significant increases in immune response activity within 5 days.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 01, 2020

                          Lead Product(s) : Pterostilbene,Sulforaphane,Green Tea Extract

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank